Document text
Economics of Vaccinating U.S. Adults ≥60
years -old against
Respiratory Syncytial Virus
UPDATED SUMMARY COMPARING MODELS FROM:
GSK,Pfizer AND University of Michigan -CDC
Ismael R. Ortega -Sanchez, PhD
NCIRD/CDC
ACIP Meeting, June 21, 2023
1Disclaimer : The findings and conclusions in this report are those of the authors and do not necessarily represent the views of
the Centers for Disease Control and Prevention.
National Center for Immunization & Respiratory Diseases
Conflict of interest
•GSK model : Daniel Molnar et al., [complete list and affiliations, upon request]
•GSK manufactures the adjuvanted RSVPreF3 vaccine
•RTI Health Solutions was funded by GSK
•Pfizer model : Derek Weycker et al., [complete list and affiliations, upon request]
•Pfizer manufacturers the bivalent RSVpreF vaccine
•Policy Analysis Inc. was funded by Pfizer
•UM-CDC model : David W Hutton et al. from Univ Michigan, …, Ismael R Ortega -
Sanchez et al. from CDC [complete list and affiliations, upon request ]
•All authors: No conflicts of interest
2
Economic analysis
Policy questions: Should adults ≥65 years of age (or ≥60 years of age) receive
one dose of Respiratory Syncytial Virus (RSV) vaccine (GSK or Pfizer product) for
the prevention of RSV disease and its complications?
Question : Is vaccinating adults aged ≥65 years (or ≥60 years) against RSV cost-
effective ?
Comparator Intervention
Base -case scenario: What is the incremental cost-effectiveness of vaccinating adults aged
≥65 years (or ≥60 years) using RSV vaccine relative to “No vaccination”?
3Unvaccinated
≥65yr -olds
(or ≥60yr -olds)Vaccinating
≥65yr -olds
(or ≥60yr -olds)
Focus on key features for model comparison
•Modeling approach
•Targeted population(s)
•Perspective (healthcare vs. societal)
•Intervention strategy and comparator
•Inputs for RSV disease burden, vaccine efficacy, and costs
•Incidence of RSV disease, rates of outcomes
•Direct and indirect costs of RSV disease
•Intervention: Vaccine efficacy , duration of protection , safety and program
costs
•Assumptions
•Strong, influential assumptions
4Note : For this and all slides, to specifically identify changes and updates from those presented last February 2023, the text wil l
appear either highlighted, marked in red or with the word updated at the top of the slide or table.
5Modeling design and assumptions
GSK Pfizer UM-CDC
Static analytical decision -making models ✔ ✔ ✔
Sensitivity analyses (and probabilistic simulation)✔(✔)✔(✔)✔
Hypothetical population ≥65yrs -old (and ≥60 -yrs-old) ✔(✔)✔(✔)✔(✔)
Time Frame: at least 2 yr. after a dose of RSV vaccine✔ ✔ ✔
Analytic Horizon: Age -specific Life Expectancy✔ ✔ ✔
Discount rate: 3% ✔ ✔ ✔
Year of economic outcomes measured: 2022 ✔ ✔ ✔
Societal perspective (and healthcare perspective)✔(✔)✔(✔)✔(✔)
6Inputs and main outcomes
Prevention of:
•Outpatient visits for RSV
•RSV hospitalizations
•RSV-associated deaths
QALYs saved
$/QALY saved
Number needed to
vaccinate (NNV) to avert an:
•Outpatient visit for RSV
•RSV hospitalization
•RSV-associated death
GSK
UpdatedPfizer
UpdatedUM-CDC
Updated
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
✔ ✔ ✔
HCRU = health care resource use
GSK, Pfizer and UM-CDC models comparison:
Selected outcome ratios for RSV vaccines (Feb 2023)
7UM-CDC
model
Vac Price
$100GSK
model
Vac Price
$148
$ / QALY gained
Vaccinating adults ≥65 yrs. 180,720 68,489
Vaccinating adults ≥60 yrs. 229,895 78,971
$ / hospitalization averted
Vaccinating adults ≥65 yrs. 101,406 57,114
Vaccinating adults ≥60 yrs. 133,992 69,638GSK vaccine
UM-CDC
model
Vac Price
$100Pfizer
model
Vac Price
$200
$ / QALY gained
Vaccinating adults ≥65 yrs. 189,407 43,749
Vaccinating adults ≥60 yrs. 233,779 50,197
$ / hospitalization averted
Vaccinating adults ≥65 yrs. 122,886 19,845
Vaccinating adults ≥60 yrs. 161,310 23,271Pfizer vaccine
GSK, Pfizer and UM-CDC models comparison:
Selected outcome ratios for RSV vaccines (June 2023)
8UM-CDC
model
Vac Price
$270GSK
model
Vac Price
$270
$ / QALY gained
Vaccinating adults ≥65 yrs. 167,301 55,088
Vaccinating adults ≥60 yrs. 205,638 64,348
$ / hospitalization averted
Vaccinating adults ≥65 yrs. 94,375 43,456
Vaccinating adults ≥60 yrs. 120,056 53,644GSK vaccine
UM-CDC
model
Vac Price
$200Pfizer
model
Vac Price
$200
$ / QALY gained
Vaccinating adults ≥65 yrs. 94,673 19,585
Vaccinating adults ≥60 yrs. 118,735 23,921
$ / hospitalization averted
Vaccinating adults ≥65 yrs. 56,571 8,797
Vaccinating adults ≥60 yrs. 75,382 10,982Pfizer vaccine
$50 $100 $150 $200
Vaccine Cost
VE against hospitalization and ED S2
Incidence of RSV hospitalization
VE against hospitalization and ED S1
Cost per Hospitalization
Outpatient QALYs Lost, Adult
Incidence of outpatient visits for RSV
Mortality, adults hospitalized with RSV
VE against oupatient illness S2
ED Incidence
Low Assumption High Assumption
$50 $100 $150 $200 $250 $300
Incidence of RSV hospitalization
VE against hospitalization and ED S2
Vaccine Cost
Outpatient QALYs Lost, Adult
Cost per Hospitalization
VE against hospitalization and ED S1
Incidence of outpatient visits for RSV
Mortality, adults hospitalized with RSV
VE against oupatient illness S2
ED IncidenceGSK: $/QALY gained (thousands)
Low Assumption High AssumptionUM-CDC model : Updated One-way Sensitivity Analyses
Base case: Age ≥65yrs; $1 67,301/QALY (GSK), $94,673/QALY (Pfizer)
9Vaccine cost per dose $270/dose (GSK) , $200/dose (Pfizer)
Two-year time frame
Age-based vaccination recommendation: ≥65 years, VE=Vaccine Efficacy LRTD= Lower Respiratory Tract Disease, S1=Season 1, S2=Seas on 2.
GSK model : Updated One-way Sensitivity Analyses
Base case: Age ≥60 years; $ 64,348 /QALY saved*
10* GSK base -case vaccine price = $270/dose, three -year time frame
Average annual incidence of first RSV ARI event
Percentage of RSV LRTD cases resulting in hospitalization
Efficacy against RSV LRTD: Waning rates first vaccination with RSVPreF3 vaccine <36 months
RSVPreF3 vaccine: Peak % efficacy after first vaccination against RSV LRTD caused by first RSV infection
Probability of death given RSV LRTD
Vaccination costs per administered dose with RSVPreF3 vaccine -Purchase cost per dose –Cost
Proportion RSV LRTD within first RSV ARI event
Baseline QALYs -General population
Efficacy against RSV ARI: Waning rates first vaccination with RSVPreF3 vaccine <36 months
RSVPreF3 vaccine: Peak % efficacy after first vaccination against first RSV ARI event
Direct cost per RSV LRTD event @ 1stinfection -Unvaccinated
Pfizer model : Updated One-way Sensitivity Analyses
Base case: Age≥60 years: $23,921/QALY saved*
11Base case
* Pfizer base -case vaccine price = $200/dose, RSV -H= RSV -associated hospitalization
GSK, Pfizer and UM-CDC models comparison:
Selected inputs
12•RSV-hospitalization rate
GSK: Proportion of medically attended RSV hospitalized cases identified by PCR, differentiated by age
(Belongia, 2018)
Pfizer : Differentiated by age and comorbidity profile (Pfizer data on file)
CDC: Differentiated by age (four RSV seasons in CDC RSV -NET data )
•Initial VE & waning over time: (updated data from GSK’s & Pfizer’s phase 3)
GSK: VE peaks in month 2, wanes linearly, reaching 0% at 34 or 43mos (depending on outcome)
Pfizer: VE is flat 7mos, wanes linearly thereafter, reaches 0% at 24mos
CDC: Step -wise: VE flat 7mos, partial drop & flat 7 -14mos ( Pfizer), 7 -18mos (GSK), reaches 0% at 24mos
•Unitary medical cost of RSV outcomes
GSK: Age -& outcome specific cost for symptomatic RSV LRTD & URTI cases (medically attended and
non-medically attended) (data from Centers for Medicare and Medicaid Services)
Pfizer: Age-, outcome -& comorbidity -specific cost for medically attended RSV illness
CDC: Age -& outcome -specific cost for medically attended RSV illness
ARI = acute respiratory infection
LRTD = lower respiratory tract disease
URTI = upper respiratory tract illness
13UM-CDC GSK Pfizer
Incidence of RSV outpatient illness
(per 100,000 persons per year)2,278
(base -case for adults ≥65 years)a1,348
(for adults ≥65 years)b2,430
(base case for adults
≥65 years)c
Incidence of RSV hospitalization
(per 100,000 persons per year)162
(base -case for adults ≥65 years)d256.3
(for adults ≥65 years)b,e300
(base -case for adults
≥65 years)c
Direct medical costs per RSV
hospitalization$21,417 –$22,425
(age -dependent)f$13,112 –$26,224
(age -dependent)g,h$12,048 –$38,380
(age -and comorbidity -
dependent)h,i
a McLaughlin et al. Open Forum Infect Dis (2022): https://doi.org/10.1093/ofid/ofac300
b Adapted from Belongia et al. Open Forum Infect Dis (2018): https://doi.org/10.1093/ofid/ofy316
c Adapted from McLaughlin et al. Open Forum Infect Dis (2022): https://doi.org/10.1093/ofid/ofac300 ; Ramirez et al. Infect Dis Ther (2023): https://doi.org/10.1007/s40121 -023-00805 -1
d RSV-NET, CDC unpublished data. Age -specific hospitalization rate per 100,000: 65.5 (60 to <65yrs), 93.8 (65 to <70yrs), 118.7 (7 0 to <75yrs) and 302.9 (75+yrs). Crude surveillance rates were
upwardly adjusted 1.5x due to incomplete case detection from reliance on upper respiratory RT -PCR (McLaughlin et al. Open Forum Infect Dis (2022): https://doi.org/10.1093/ofid/ofac300
e Adapted from Falsey et al. NEJM (2005): https://doi.org/10.1056/nejmoa043951 ; Herring et al. Vaccine (2022): https://doi.org/10.1016/j.vaccine.2021.12.002
f Ackerson et al. J Infect Dis (2020). Updated to Q3 2022$ using GDP Deflator: https://doi.org/10.1093/infdis/jiaa183 ; Branche et al. Clin Infect Dis (2022): https://doi.org/10.1093/cid/ciab595
g CMS Medicare Inpatient Hospitals (DRG Average Payments from 2019 dataset)
h Kaiser Family Foundation (How much more than Medicare do private insurers pay? 2020): https://www.kff.org/medicare/issue -brief/how -much -more -than -medicare -do-private -insurers -
pay-a-review -of-the-literature/
i Merative MarketScan Commercial Claims and Encounters (CCAE) and Medicare Supplemental Coordination of Benefits (MDCR) Databases (2016 -2019)GSK, Pfizer and UM-CDC models: Key differences in
model inputs
UM-CDC model : Sensitivity of Cost per QALY saved to RSV -Related
Hospitalization Rates among Adults ≥65 years: 2-year timeframe
14Base case for Pfizer and GSK are shown with blue and orange solid filled diamond markers, respectively : Estimated using the adjusted mean RSV -related hospitalization rate over RSV seasons: 2015 -16,
2016 -17, 2017 -18, and 2018 -19. Adjusted rate for lower sensitivity of PCR testing. CDC RSVnet
Blue ball markers : Estimated usin g Pfizer vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Orange ball markers : Estimated usin g GSK vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Labels in markers: They refer to the specific source of the RSV -associated hospitalization rate used in the estimation of either vaccine cost per QALY saved. Parentheses include either the year of the
publication or the place where the data for the study was collected. Pfizer BasePfizer Branche (Rochester)
Pfizer Branche (NYC)
Pfizer Belongia
Pfizer Widmer (2012)Pfizer Widmer (2014)GSK BaseGSK Branche (Rochester)
GSK Branche (NYC)
GSK Belongia
GSK Widmer (2012)GSK Widmer (2014)
$- $40,000 $80,000 $120,000 $160,000 $200,000 $240,000
- 50 100 150 200 250 300Incremental cost per QALY gained
RSV-related hospitalization rate per 100,000
UM-CDC model : Sensitivity of Cost per QALY saved to RSV -Related
Hospitalization Rates among Adults ≥65 years: 2-year timeframe
15Pfizer BasePfizer Branche (Rochester)
Pfizer Branche (NYC)
Pfizer Belongia
Pfizer Widmer (2012)Pfizer Widmer (2014)GSK BaseGSK Branche (Rochester)
GSK Branche (NYC)
GSK Belongia
GSK Widmer (2012)GSK Widmer (2014)
$- $40,000 $80,000 $120,000 $160,000 $200,000 $240,000
- 50 100 150 200 250 300Incremental cost per QALY gained
RSV-related hospitalization rate per 100,000
Base case for Pfizer and GSK are shown with blue and orange solid filled diamond markers, respectively : Estimated using the adjusted mean RSV -related hospitalization rate over RSV seasons: 2015 -16,
2016 -17, 2017 -18, and 2018 -19. Adjusted rate for lower sensitivity of PCR testing. CDC RSVnet
Blue ball markers : Estimated usin g Pfizer vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Orange ball markers : Estimated usin g GSK vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Labels in markers: They refer to the specific source of the RSV -associated hospitalization rate used in the estimation of either vaccine cost per QALY saved. Parentheses include either the year of the
publication or the place where the data for the study was collected.
UM-CDC model : Sensitivity of Cost per QALY saved to RSV -Related
Hospitalization Rates among Adults ≥65 years: 2-year timeframe
16Pfizer BasePfizer Branche (Rochester)
Pfizer Branche (NYC)
Pfizer Belongia
Pfizer Widmer (2012)Pfizer Widmer (2014)GSK BaseGSK Branche (Rochester)
GSK Branche (NYC)
GSK Belongia
GSK Widmer (2012)GSK Widmer (2014)
$- $40,000 $80,000 $120,000 $160,000 $200,000 $240,000
- 50 100 150 200 250 300Incremental cost per QALY gained
RSV-related hospitalization rate per 100,000$55.1K, GSK (3-yr TF)
$19.6K, Pfizer
Base case for Pfizer and GSK are shown with blue and orange solid filled diamond markers, respectively : Estimated using the adjusted mean RSV -related hospitalization rate over RSV seasons: 2015 -16,
2016 -17, 2017 -18, and 2018 -19. Adjusted rate for lower sensitivity of PCR testing. CDC RSVnet
Blue ball markers : Estimated usin g Pfizer vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Orange ball markers : Estimated usin g GSK vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Labels in markers: They refer to the specific source of the RSV -associated hospitalization rate used in the estimation of either vaccine cost per QALY saved. Parentheses include either the year of the
publication or the place where the data for the study was collected.
UM-CDC model : Sensitivity of Cost per QALY saved to RSV -Related
Hospitalization Rates among Adults ≥65 years: 2-year timeframe
17Pfizer BasePfizer Branche (Rochester)
Pfizer Branche (NYC)
Pfizer Belongia
Pfizer Widmer (2012)Pfizer Widmer (2014)GSK BaseGSK Branche (Rochester)
GSK Branche (NYC)
GSK Belongia
GSK Widmer (2012)GSK Widmer (2014)
$- $40,000 $80,000 $120,000 $160,000 $200,000 $240,000
- 50 100 150 200 250 300Incremental cost per QALY gained
RSV-related hospitalization rate per 100,000$70.1K, GSK (2-yr TF)
$19.6K, Pfizer
Base case for Pfizer and GSK are shown with blue and orange solid filled diamond markers, respectively : Estimated using the adjusted mean RSV -related hospitalization rate over RSV seasons: 2015 -16,
2016 -17, 2017 -18, and 2018 -19. Adjusted rate for lower sensitivity of PCR testing. CDC RSVnet
Blue ball markers : Estimated usin g Pfizer vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Orange ball markers : Estimated usin g GSK vaccine VE and price input data for the specific hospitalization rate as reported by the reference .
Labels in markers: They refer to the specific source of the RSV -associated hospitalization rate used in the estimation of either vaccine cost per QALY saved. Parentheses include either the year of the
publication or the place where the data for the study was collected.
GSK, Pfizer and UM-CDC: Initial or Early Peak of
Vaccine Efficacy & Decline in Season 2 ( updated )
18a VE over median (GSK) or mean (Pfizer) 7 months for season 1, VE through a median 18 months (GSK) or 14 months (Pfizer) for season 2 as reported in the follow up in phase 3 clinical trials
b Manufacturer phase 3 trial data; VE against medically attended acute respiratory illness
c GSK phase 3 trial data; VE against acute respiratory illness, regardless of whether medically attended. Reported peak value atmonth 2.
d GSK phase 3 trial data; VE against medically attended lower respiratory tract disease
e Pfizer phase 3 trial data; VE against medically attended lower respiratory tract illness with ≥3 lower respiratory symptoms
f GSK phase 3 trial data; VE against lower respiratory tract disease, regardless of whether medically attended. Reported peak value at month 2.UM-CDC Model GSK Model Pfizer Model
GSK vaccine Pfizer vaccine GSK vaccine Pfizer vaccine
Vaccine efficacy (VE) against RSV
outpatient illnessa Season 179.0
(54.3 –91.5)b65.2
(36.0 –82.0)bSeason 1 Peak: 74.2
(56.4 –94.0)
Weighted linear regression
over time of estimated
efficacy from clinical trialc65.1
(35.9 –82.0)b
Season 227.8
(0 –60.4)b55.0
(0 –82.0)b55.0
(95% CI: -3.4–82.0)b
VE against RSV hospitalization and
emergency department visitaSeason 187.5
(58.9 –97.6 )d84.6
(32.0 –98.3)eSeason 1 Peak: 88.0
(65.8 –99.2)
Weighted linear regression
over time of estimated
efficacy from clinical trialf84.6
(32.0 –98.3)e
Season 252.9
(0 –81.2)d75.0
(0 –97.4)e75.0
(95% CI: -25.3 –97.4)e
GSK, Pfizer and UM-CDC: Assumption on waning of
vaccine efficacy (VE) per outcome ( Feb 2023 )
19GSKVE peaks at 2 months then wanes per month
RSV-ARI = 5.36% points per month (range: 0.00 -
13.37%)
RSV-LRTD = 2.63% points per month (range: 0.00 -
10.95%)
No residual protection after 12 monthsPfizerInitial VE assumed to persist for 7 months,
Then to decline linearly to 0% effectiveness at 24
months
Residual though declining protection up to 24
monthsUM-CDCVaccine and outcome -specific
For both vaccines:
Exponential decay up to 12 months
and then 0% afterwards; calibrated such that the
first 6 months VE equals the trial estimate
GSK, Pfizer and UM-CDC: Assumption on waning of
vaccine efficacy (VE) per vaccine & outcome ( June 2023 )
20
GSK
UM-CDC UM-CDC
The pink -shaded areas denote a higher level of uncertainty of the waning assumption beyond available phase 3 data
Feb 2023GSK: Residual Vaccine Effectiveness (Feb 2023
ACIP) and updated analyses ( June 2023 )
21RSV LRTD : 50% of peak VE ( 88% )
assumed in month 1, peak VE
declines by 2.10% (2.63% in Feb)
monthly rate beginning in month 2
though 20-month maximum follow
up of trial . Assumed to follow
linear decline trend afterwards.
Reaches 0% in month 43
RSV ARI : 50% of peak VE ( 74% )
assumed in month 1, peak VE
declines by 2.26% (5.36% in Feb)
monthly rate beginning in month 2
though 20-month maximum follow
up of trial . Assumed to follow
linear decline trend afterwards.
Reaches 0% in month 34
The pink -shaded area denotes a higher level of uncertainty of the waning assumption beyond
available phase 3 data
Pfizer : Residual Vaccine Effectiveness (Feb
2023 ACIP) and updated analyses ( June 2023 )
22
Hospitalization or ED : Initial
VE (84.6%) assumed to
persist for 7 months, to
decline to 75% at 14 months,
and then decline to 0% at
24thmonth
Outpatient : Initial VE ( 65.1% )
assumed to persist for 7
months, to decline to 55% at
14 months, and then decline
to 0% at 24thmonth
The pink -shaded area denotes a higher level of uncertainty of the waning assumption beyond
available phase 3 data
UM-CDC: Updated assumption on waning of
vaccine efficacy per vaccine and outcome
23Hospitalization or ED: Initial VE (87.5%
GSK; 84.6% Pfizer ) assumed to persist
for 7 months, to drop to 52.9% ( GSK),
75%( Pfizer) and remain flat from
month 8 to month 18 ( GSK) or month
14 (Pfizer ), and then decline linearly to
0% at month 24.
Medically attended (Outpatient):
Initial VE (79% GSK; 65.2% Pfizer )
assumed to persist for 7 months, to
drop to 27.8% ( GSK), 55%( Pfizer ) and
remain flat from month 8 to month 18
(GSK), month 14 ( Pfizer ), and then
decline linearly to 0% at month 24
GSK
Pfizer87.5%
52.9%79.0%
27.8%
84.6%
75.0%
65.2%
55.0%
The pink rectangle highlights the difference in duration of protection assumption between vaccines
Comparison of GSK and Pfizer vaccines: Update base
case & scenario $/QALY results using UM-CDC model
24aIncidence rates: Lower incidence assumes 95% RT -PCR test sensitivity, Higher rate incorporates the upper limit of the 95% CI ar ound the base case incidence rate
estimate.
b Recommendation = vaccination at age ≥65 years; incidence rates of RSV outcomes upwardly adjust 1.5x to account for incomple te RT-PCR sensitivity on a
respiratory specimen (McLaughlin et al; Open Forum Infect Dis 2022); vaccine efficacy only considered for two years post -vaccina tionScenario GSK Pfizer
Vaccinating adults aged 60 to <65 years only $372,656 $218,250
Lower incidence of RSVain adults ≥65 years $276,393 $161,487
Vaccine cost $340 per dose $220,864 $187,865
Vaccinating adults ≥60 years, $205,638 $118,735
Residual vaccine protection = 0% at 18 (GSK) or 14 (Pfizer) months $170,022 $135,886
Base caseb(Vacc price $270 GSK, $200 Pfizer , adults ≥65yrs) $167,301 $94,673
Vaccine cost $180 per dose $98,485 $81,358
Higher incidence of RSVbin adults ≥65 years $84,736 $40,467
Limitations
25•Factors not considered that may result in overestimating the ICER
(underestimating the cost -effectiveness) of RSV vaccination
•All of the 3 models assumed no indirect effects of vaccination (i.e., no protection against RSV
transmission)
Except UM-CDC model
•Manufacturers models do not include RSV -related medical costs incurred after discharge
from an RSV -associated hospitalization or emergency department visit:
•Stay in long -term care or rehabilitation facility
•Manufacturers models do not include potential vaccine -associated serious
adverse events (SAEs)
•Quality of life impact, resource utilization and costs associated with hypothetical SAEs
•Vaccine efficacy beyond clinical trial follow -up time (beyond 14 months, Pfizer
or 18 months, GSK) is unknown
•All 3 models assumed non -zero declining efficacy beyond 14 or18 months
Conclusion
26•Differences in key inputs among GSK, Pfizer and UM-CDC models explain differences in results:
•Annual incidence of RSV hospitalization and outpatient disease
•Initial vaccine (season 1) and waning of protection (VE season 2+)
•Selection of medical costs sources and data extraction approach
•Resulting ICERs depended heavily on assumptions and selection of input data
•Annual incidence of RSV Hospitalization
•Vaccine costs (e.g., increase in GSK vaccine price)
•Base -case in the 3 models:
•Vaccination would significantly reduce RSV disease burden in older adults
•VE clinical trials data and assumptions support impact on disease reduction
•Economic value of RSV vaccines appear to be costly and could be cost-effective
•RSV incidence, related healthcare costs, initial VE and duration combined with reasonable
vaccine price would determine the cost-effectiveness value of RSV vaccination
Acknowledgements
From NCIRD/CDC
•Michael Melgar
•Jamison Pike
•Fiona Havers
•Amadea Britton
Also:
•Adult RSV working group members
•Andrew Leidner and the Econ Team members at ISD/NCIRD
27